Amitriptyline

Amitriptyline is indicated for: • the treatment of major depressive disorder in adults • the treatment of neuropathic pain in adults • the prophylactic treatment of chronic tension type headache (CTTH) in adults • the prophylactic treatment of migraine in adults • the treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products.

This medicinal product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis.

INDICATIONS AND USAGE

For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than are other depressive states.

Amitriptyline Hydrochloride Tablets USP (amitriptyline hydrochloride) is indicated for: • Drug management of depressive illness. • Depressive illness of psychotic or endogenous nature and in selected patients with neurotic depression.

Endogenous depression is more likely to be alleviated than are other depressive states. Amitriptyline Hydrochloride Tablets USP, because of its sedative action, is also of value in alleviating the anxiety component of depression. As with other tricyclic antidepressants, Amitriptyline Hydrochloride Tablets USP may precipitate hypomanic episodes in patients with bipolar depression.

These drugs are not indicated in mild depressive states and depressive reactions. 1 Pediatrics Pediatrics (˂ 18 years of age): Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Geriatrics: Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness.